Trial Profile
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Antineoplastics
- Indications Cervical cancer
- Focus Therapeutic Use
- 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record.
- 14 Sep 2011 New trial record